IP Law 360

OCTOBER 13, 2021

Investors in a company developing a cutting-edge cancer therapy that AstraZeneca PLC bought in 2013 but never brought to market struggled to convince Delaware's Supreme Court on Wednesday that they deserved milestone payments for the drug's aborted development.

Marketing 40

Marketing Marketing 40

IP Tech Blog

AUGUST 18, 2023

Although most of the patent linkage court decisions so far are in favor of generic applicants, in AstraZeneca plc v. AstraZeneca v. Guowei,” decided in June, 2023), the Supreme People’s Court (SPC) issued a final decision partially in favor of brand company AstraZeneca related to the drug dapagliflozin (brand name Forxiga).

Litigation 98

Litigation Patent Intellectual Property Branding 98

LexBlog IP

AUGUST 18, 2023

Although most of the patent linkage court decisions so far are in favor of generic applicants, in AstraZeneca plc v. Ltd. (“AstraZeneca v. This is the first case in which the SPC found a generic applicant’s product falls into the scope of a brand company’s patent. Sichuan Guowei Co. ZL201210201489.X,

Litigation 52

Litigation Patent Intellectual Property Branding 52